Straumann Holding AG / Key word(s): Half Year Results/Miscellaneous 15-Aug-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The
Dive Brief: The Food and Drug Administration has published final guidance on devices for determining the susceptibility of bacterial or fungal pathogens to different antimicrobial
Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated